NovaSight key facts
as of Oct 2026- Developer of a pediatric ophthalmology medical device intended to integrate data analytics into a range of medical devices.
- NovaSight is valued at approximately $47.3M as of Oct 2026 (last reported valuation).
- It has raised $38.3M; the latest was Later Stage VC ($7.9M) in Aug 2025.
- Notable investors include Innovation Authority, Yunjin (Suzhou) Capital Management, Arbelon Holdings, Club 100 plus, Dagesh — 9 tracked in total.
- Status: Privately Held (backing).
NovaSight's last reported valuation, Aug 2025. Nothing priced has surfaced since.
- ·Watch NovaSight: the Monday email on marks, rounds and moves
NovaSight funding rounds
No funding rounds for NovaSight are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
NovaSight valuation
NovaSight's last reported valuation was $47.3 million in Aug 2025. No priced round, secondary trade or fund mark has surfaced since.
NovaSight investors
9 investors are on record for NovaSight, including Innovation Authority, Yunjin (Suzhou) Capital Management, Arbelon Holdings and Club 100 plus.
About NovaSight
Developer of a pediatric ophthalmology medical device intended to integrate data analytics into a range of medical devices. The company aims to prevent vision impairments among pediatric patients using eye-tracking-based technology in novel diagnostic, therapeutic, and preventive solutions that are designed for the unique needs and attention span of children, enabling patients to receive the right eye care devices required.
- Sector
- Healthcare
- HQ
- Lod, Israel
- Founded
- 2016
- Employees
- 14
- Website
- nova-sight.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.